Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 4
4 · Nuvalent, Inc. · Filed Aug 3, 2021
Insider Transaction Report
Form 4
Nuvalent, Inc.NUVL
Transactions
- Conversion
Series B Preferred Stock
2021-08-02−4,831,384→ 0 total→ Class A Common Stock (897,671 underlying) - Conversion
Class A Common Stock
2021-08-02+897,671→ 897,671 total
Footnotes (1)
- [F1]Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into 0.1858 shares of the Issuer's Class A Common Stock. The Series B Preferred Stock had no expiration date.